Open access
Open access
Powered by Google Translator Translator

Oncology – Urological

Review: Recent Advances in the Management of Metastatic Prostate Cancer

1 Oct, 2021 | 09:55h | UTC

Recent Advances in the Management of Metastatic Prostate Cancer – JCO Oncology Practice

 


Clinical Review on the Management of Metastatic Renal Cell Carcinoma.

26 Sep, 2021 | 21:41h | UTC

Clinical Review on the Management of Metastatic Renal Cell Carcinoma – JCO Oncology Practice

 


Cohort study: Half of men with low-risk prostate cancer move from surveillance to treatment within a few years.

27 Aug, 2021 | 08:26h | UTC

Half of men with low-risk prostate cancer move from surveillance to treatment within a few years – Health Imaging

Original study: Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study – Journal of Urology

 


RCT: New blood test could improve prostate cancer screening.

17 Aug, 2021 | 08:48h | UTC

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

News release: New blood test improves prostate cancer screening – Karolinska Institutet

Related:

RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

 

Commentary on Twitter

 


Study: many patients with small renal masses can be safely managed with active surveillance.

2 Aug, 2021 | 00:07h | UTC

Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention – The Journal of Urology

Commentary: More Data Support Active Surveillance for Small Renal Masses — Most patients avoided surgery with no metastasis, better focus on aggressive disease – MedPage Today (free registration required)

 


RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

9 Jul, 2021 | 10:03h | UTC

MRI-Targeted or Standard Biopsy in Prostate Cancer Screening – New England Journal of Medicine (link to abstract – $ for full-text)

News release: MRI can cut overdiagnoses in prostate-cancer screening by half – Karolinska Institutet

Related articles: RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer AND Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer AND Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis AND Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer AND Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer AND Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy AND Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer AND Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis AND Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer

 


RCT: Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer.

24 Jun, 2021 | 09:41h | UTC

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 


RCT: Adjuvant Nivolumab vs. Placebo in Muscle-Invasive Urothelial Carcinoma.

3 Jun, 2021 | 10:36h | UTC

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma – New England Journal of Medicine

 


AUA Guideline | Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up.

2 Jun, 2021 | 08:27h | UTC

Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up – American Urological Association

Commentary: AUA updates guideline on renal masses and localized renal cancer – Urology Times

 


M-A: A biofeedback‐guided program or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy.

26 May, 2021 | 08:13h | UTC

A biofeedback‐guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta‐analysis and systematic review – The International Journal of Clinical Practice

 


RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.

10 May, 2021 | 00:46h | UTC

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link to abstract – $ for full-text)

 


Final Survival Analysis: Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer

4 May, 2021 | 08:26h | UTC

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study – Journal of Clinical Oncology

 

Commentary on Twitter

 


AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies

29 Apr, 2021 | 08:33h | UTC

Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association – Circulation: Genomic and Precision Medicine

News release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association

Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association

Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay

 


Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review

18 Apr, 2021 | 21:16h | UTC

Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review – The Journal of Urology

Commentary: Review: For many men with prostate cancer, surgery risks outweigh potential benefits – U.S. Department of Veteran Affairs

 


M-A: Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy

18 Apr, 2021 | 21:14h | UTC

Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis – The Journal of Urology

 


RCT: Better continence after 3 months with robotic-assisted compared with laparoscopic radical prostatectomy

18 Apr, 2021 | 21:11h | UTC

Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01) – European Urology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: Nivolumab plus Cabozantinib vs. Sunitinib for Advanced Renal-Cell Carcinoma

4 Mar, 2021 | 08:33h | UTC

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

 


M-A: Local salvage therapies after radiotherapy for prostate cancer

3 Mar, 2021 | 08:06h | UTC

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) – European Urology (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


RCT: Extended vs. limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer

3 Mar, 2021 | 08:05h | UTC

Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial – European Urology (link to abstract – $ for full-text)

Commentary: Extended pelvic lymph node dissection during RP does not appear beneficial – Urology Times

 

Commentary on Twitter

 


Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update

21 Feb, 2021 | 21:47h | UTC

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 


Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging

16 Feb, 2021 | 01:50h | UTC

Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study – JAMA Oncology

Commentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)

 

Commentary on Twitter

 


RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

15 Feb, 2021 | 00:36h | UTC

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Immunotherapy – targeted drug combination improves survival in advanced kidney cancer – Dana-Farber Cancer Institute

 

Commentary on Twitter

 


RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

15 Feb, 2021 | 00:34h | UTC

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: 2021 Genitourinary Cancers Symposium: Enfortumab Vedotin-ejfv Prolongs Survival in Patients With Metastatic Urothelial Carcinoma – The ASCO Post

 


RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma

15 Feb, 2021 | 00:32h | UTC

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress

 


RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer

15 Feb, 2021 | 00:29h | UTC

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today

 


Stay Updated in Your Specialty

No spam, just news.